Introduction
Despite advances in human leukocyte antigen (HLA) typing, graft engineering, and supportive care, reducing the incidence and severity of graft-versus-host disease (GvHD) remains a significant challenge to successful outcomes for patients undergoing allogeneic blood or marrow transplantation (alloBMT) [1] . GvHD is caused by immune reactions of donor T cells against disparate host histocompatibility antigens [2] . Current GvHD prophylaxis regimens impair alloreactive T cell activation, proliferation, and interleukin-2 (IL-2) production and interfere with apoptosis of alloreactive T cells [3, 4] leading to global immunosuppression and delayed induction of transplantation tolerance [5] . Among currently used immunosuppressants, only methotrexate (MTX) and cyclophosphamide can induce the apoptosis of alloantigen-activated human T cells [3] . Although active as a single agent for GvHD prevention, MTX is toxic and cannot be administered in the high doses required for alloreactive T cell apoptosis and tolerance induction [3] . In contrast, cyclophosphamide can be administered safely in the high doses that may be required to eliminate alloantigen-activated T cells after alloBMT. We have shown that a single dose of posttransplantation cyclophosphamide (200 mg/kg) augments the engraftment of major histocompatibility complex (MHC)-mismatched bone marrow in mice conditioned with the combination of pretransplantation fludarabine and low-dose (200 cGy) total body irradiation [6] . In addition, posttransplantation cyclophosphamide reduced the incidence and severity of GvHD across MHC barriers after myeloablative conditioning. These observations were not entirely novel because cyclophosphamide administration was one of the first strategies shown to be effective in controlling acute GvHD in rodents [7, 8] . However, in an early clinical trial, intermittent low doses of posttransplantation cyclophosphamide were inferior to cyclosporine in preventing GvHD after HLA-matched alloBMT [9] . Thus, the drug may have been given at the wrong time or at a dose that was too low to be maximally effective at suppressing GvHD. The selection of low, intermittent doses of cyclophosphamide was motivated by concerns that higher doses of the drug might be toxic to donor stem cells and would therefore impair engraftment. Our preclinical work as well as other data that have shown that high-dose cyclophosphamide is not toxic to primitive hematopoietic stem cells provided the rationale to test this approach in the clinical setting [10] [11] [12] . Here, we describe the development and clinical use of high-dose cyclophosphamide as an approach for GvHD prophylaxis and review outcomes from several early-phase clinical trials using this strategy in the HLA-matched and mismatched settings.
Clinical translation of high-dose posttransplantation cyclophosphamide: initial studies
Crossing the HLA barrier in alloBMT is one of the most formidable challenges in clinical transplantation immunology. Historically, partially HLA-mismatched, or HLA-haploidentical, alloBMT has been associated with high rates of graft failure, severe GvHD, and nonrelapse mortality (NRM) [13] . Increasing HLA mismatch between donor and recipient has been associated with worse event-free survival (EFS), especially when donors are mismatched by two or more HLA antigens [14] . Two independent phase I/II clinical trials evaluated the safety and efficacy of high-dose posttransplantation cyclophosphamide, given in conjunction with mycophenolate mofetil (MMF) and tacrolimus after nonmyeloablative conditioning and partially HLA-mismatched bone marrow transplantation (mini-haploBMT) [15, 16] . All patients were treated initially as outpatients and received conditioning modified slightly from the regimen of McSweeney et al. [17] : fludarabine, low-dose cyclophosphamide, and 200 cGy total body irradiation; after transplantation of T cell replete donor bone marrow (on what is designated day 0), the patients received 50 mg/kg of cyclophosphamide on day 3 (28 patients) or on days 3 and 4 (40 patients) [15] . Administration of tacrolimus (for 6 months) and MMF (for 35 days) was not initiated until the day following completion of posttransplantation cyclophosphamide to avoid blocking cyclophosphamideinduced tolerance [18] . The median times to neutrophil and platelet recovery were 15 and 24 days, respectively. Graft failure occurred in nine of 66 (13%) evaluable patients and was fatal in one. The cumulative incidences of acute grades II-IV and grades III-IV GvHD were 34 and 6%, respectively. The cumulative incidence of NRM at 1 year was 15%. There was a trend toward a lower incidence of extensive chronic GvHD among recipients of two versus one dose of posttransplantation cyclophosphamide (5 versus 25%, P ¼ 0.05), the only difference in outcomes between these two groups of patients. Serious infections were relatively infrequent: there were no cases of cytomegalovirus (CMV) disease and only five cases of invasive fungal infection, two of which were fatal. It also appears that this strategy may allow the preservation of fertility in young women [19] . These encouraging outcomes in patients with advanced hematologic malignancies served as a rationale for further studies in patients with hematologic malignancies and in those with lifethreatening nonmalignant hematologic diseases.
Extended studies of nonmyeloablative, HLAhaploidentical BMT (mini-haploBMT) with posttransplantation cyclophosphamide
We recently reported on the outcomes of 185 hematologic malignancies patients treated with mini-haploBMT and high-dose posttransplantation cyclophosphamide [20 ] . Most patients (median age 50, range 1-71) had advanced disease and 49 (26%) had failed autologous BMT. Diagnoses were acute leukemia or lymphoblastic lymphoma (58), non-Hodgkin lymphoma (42), Hodgkin lymphoma (25) , myelodysplastic syndrome (MDS) (22) , chronic lymphocytic leukemia (CLL) (15) , chronic myeloid leukemia (CML) (11), multiple myeloma (9), and chronic myelomonocytic leukemia (CMML) (3). Molecular typing was at an allele level for HLA-A, HLA-B, HLA-Cw, and HLA-DRB1 and at an allele group level for HLA -DQB1. Patients and their donors were heavily mismatched, with 159 pairs mismatched for 3 or 4 HLA antigens (HLA-A, HLA-B, HLA-Cw, or HLA-DRB1, not including HLA-DQB1) in any direction. Posttransplant GvHD prophylaxis consisted of cyclophosphamide (50 mg/kg intravenously) either once (on day 3; n ¼ 48) or twice (on days 3, 4; n ¼ 137), MMF, and tacrolimus as already described. Nonengraftment attributed to primary graft failure or to residual bone marrow malignancy occurred in 29 of 177 evaluable patients (16%). Only three of these patients died in aplasia without evidence of disease persistence or recurrence. The cumulative incidences of NRM and relapse or progression at 1 year after transplantation were 15 and 50%, respectively. The cumulative incidence of grades II-IV acute GvHD by day 200 after transplantation was 31% and of chronic GvHD by 1 year after transplantation was 15%. With a median of 20 months follow-up after BMT (range 2-71 months), the actuarial EFS at 1 year was 35%. Figure 1 shows the EFS of 144 patients transplanted before March 2009 according to their primary diagnosis. The EFS curves appear to achieve a plateau of 20-30% for diseases such as MDS and the acute leukemias (Fig. 1a ) versus 40-50% for diseases such as nonHodgkin lymphoma (excluding mantle cell lymphoma) and Hodgkin lymphoma (Fig. 1b) . The results of minihaploBMT with posttransplantation cyclophosphamide for Hodgkin lymphoma are particularly encouraging because all but two of the patients had relapsed after a prior autologous BMT. In light of the generally poor outcomes of nonmyeloablative, HLA-matched BMT for Hodgkin lymphoma [21] , our results raise the possibility that T and/or natural killer cells reactive to HLA molecules may be uniquely effective in the treatment of multiply relapsed Hodgkin lymphoma.
The major challenge in HLA-haploidentical BMT is not finding a donor, but rather selecting among multiple potential donors. Historically, the extent of HLA mismatch between donor and recipient has been the paramount consideration in donor selection, because increasing degrees of HLA mismatch have been associated with worse overall outcomes [13, 22] . The low incidence of severe GvHD [15] and NRM prompted us to examine the relationship between HLA mismatch and outcome of mini-haploBMT with posttransplantation cyclophosphamide. Notably, increasing degrees of HLA mismatch at either class I or class II loci had no significant effect on the cumulative incidence of acute or chronic GvHD or on NRM. Moreover, the presence of a HLA-DRB1 antigen mismatch in the graft-versus-host (GvH) direction was associated with a significantly lower cumulative incidence of relapse ( Fig. 2a ; P ¼ 0.04) and improved EFS ( Fig. 2b ; P ¼ 0.009) [23] , whereas DQB1 antigen and class II allele mismatch status had no effect. Additionally, the presence of two or more class I allele mismatches (composite of A, B, and Cw) in either direction was associated with a significantly lower cumulative incidence of relapse ( Fig. 2c ; P ¼ 0.045 for GvH direction, P ¼ 0.01 for HvG direction) and improved EFS ( Fig. 2d ; P ¼ 0.07 for GvH direction, P ¼ 0.001 for HvG direction). Thus, when nonmyeloablative, HLA-haploidentical BMT incorporates high-dose posttransplantation cyclophosphamide, increasing HLA disparity between donor and recipient was not detrimental to overall outcome and appeared to be beneficial. Although the results of this retrospective analysis need to be validated prospectively, the results raise the possibility that posttransplantation cyclophosphamide dissociates the graft-versus-leukemia (GvL) effect from clinically significant GvHD, and that donors for alloBMT could be selected based upon genetic factors other than HLA.
The application of BMT to treat nonmalignant disorders affecting the lymphohematopoietic system, especially sickle cell anemia, is limited by the lack of suitable donors [24] . Nonmyeloablative, HLA-haploidentical BMT with posttransplant cyclophosphamide is a promising approach for patients with life-threatening nonmalignant hematologic disease who lack an HLA-matched sibling donor. We treated three patients with thrombotic PNH, one of whom also had sickle cell disease, with a nonmyeloablative, HLA-haploidentical BMT with posttransplant cyclophosphamide [25] . Rapid engraftment without GvHD occurred in two of the patients, including the patient with sickle cell disease. Both patients are disease-free with full donor chimerism and require no immunosuppressive therapy, with follow-up of 1 and 4 years, respectively.
High-dose cyclophosphamide as sole GvHD prophylaxis after HLA-matched alloHSCT
There is no consensus regarding the most effective and least toxic approach for GvHD prevention after HLAmatched alloBMT [26] . The most commonly used regimens for GvHD prophylaxis consist of a calcineurin inhibitor (CNI; cyclosporine or tacrolimus) in combination with either MTX, MMF, or sirolimus [27] [28] [29] [30] [31] .
Graft However, despite the use of pharmacological GvHD prophylaxis, acute GvHD still occurs in 35-55% of BMT recipients from HLA-matched siblings, and more frequently in recipients of unrelated donor BMT [29, [31] [32] [33] [34] . As importantly, the incidence of chronic GvHD is 50% or higher with most commonly used prophylaxis regimens [27] [28] [29] [30] [31] 35, 36] . Patients that do not develop chronic GvHD can be withdrawn from immune suppression within 6-9 months of transplantation. These patients are considered to have developed early donor/ recipient tolerance. Patients that develop acute GvHD require secondary treatment and the majority of them remain on multiagent immunosuppression beyond the first 12 months after transplantation [37] . The median duration of immunosuppressive treatment in patients that develop chronic GvHD is 23 months with approximately 15% of them requiring treatment beyond 7 years [38] . Thus, it can be argued that the frequency and duration of use of secondary immunosuppression should be considered when judging the efficacy of any GvHD prophylaxis regimen [39] . A GvHD prophylaxis strategy that promotes tolerance induction may obviate the need for secondary immunosuppressive treatment. By avoiding the use of CNIs, such an approach may also improve immune reconstitution and optimize antitumor immunity [40, 41] . It has been proposed that CNIs by disrupting the thymic architecture [42] and by blocking the induction of transplantation tolerance [5] could also play a role in the development of chronic GvHD [43, 44] . Thus, their omission may decrease the incidence of chronic GvHD.
On the basis of the results with high-dose cyclophosphamide as GvHD prophylaxis in mismatched alloBMT, we studied it as sole prophylaxis of GvHD after myeloablative HLA-matched related or unrelated donor BMT [45 ] . One hundred seventeen consecutive hematologic malignancies patients were treated on this phase I/II clinical trial; 78 patients received HLA-matched related and 39 received HLA-matched unrelated donor allografts. Transplantation conditioning comprised oral or intravenous busulfan from days À7 to À4 (target AUC 800-1400) and cyclophosphamide 50 mg/kg on days À3 and À2, followed by an infusion of donor marrow obtained in a targeted collection of 4 Â 10 [8] nucleated cells/kg. No growth factors were administered. The median patient age was 50 years with 14 patients being 60 years or older. The most common diagnosis was acute myeloid leukemia (AML; n ¼ 58, or 50%), and 68/117 patients (58%) were not in remission at the time of transplantation. Sustained engraftment of donor cells occurred in 114 patients (98%), Outcomes (relapse and nonrelapse mortality) according to donor-recipient human leukocyte antigen (HLA) mismatch (a, b). Event-free survival according to the number of antigen mismatches (c, d). Adapted with permission from [23] .
with the median time to neutrophil recovery of 23 days for recipients of related donor and 25 days for recipients of unrelated donor allografts. High-dose posttransplantation cyclophosphamide was well tolerated; the most common toxicities were transient mild renal dysfunction or elevations of serum liver enzymes, but hepatic venoocclusive disease developed in 10 patients (9%) and was fatal in 2. The cumulative incidences of grades II-IV GvHD by day 200 after transplantation were 42 and 46% among recipients of related and unrelated donor grafts, respectively. The incidence of grades III-IV GvHD for all patients was 10%. At 2 years after transplantation, the cumulative incidences of chronic GvHD for recipients of related and unrelated donor grafts were 9 and 11%, respectively. In a multivariable analysis, the only variable associated with an increased risk of developing moderate-severe acute GvHD was a male recipient of a female donor graft (P ¼ 0.05).
These initial results were recently updated in a follow-up report on 139 consecutive patients (79 related and 60 unrelated) treated on this study [46] . With a median follow-up of 26 months, the cumulative incidences of acute grades II-IV and chronic GvHD for all patients were 45 and 10%, respectively. Only three patients have died with refractory GvHD. We also retrospectively analyzed the use of secondary systemic immunosuppressants (SSIs) in this expanded cohort. Overall, the cumulative incidence of SSI use was 45%. The median time to initiation of SSIs was 42 days (range 19-142 days) and the median duration of SSI use was 152 days (range 13-981 days). At 6 months and 1 year after transplantation, 63 and 85% of patients were off all immunosuppressive therapy, respectively. These results extend our previous observations that posttransplantation cyclophosphamide is effective single agent prophylaxis of acute GvHD with a low rate of grades III-IV GvHD and more than half of the patients never requiring additional SSIs. The limited use of SSIs may be responsible for the low infection rate seen in these patients.
The overall survival (OS) and EFS for all patients at 1 year after transplantation were 63 and 48%, respectively, and at 2 years after transplantation were 55 and 39%, respectively, suggesting that use of high-dose cyclophosphamide for GvHD prophylaxis retains the GvL effect in these high-risk patients [45 ] . Consistent with other recent studies, EFS and OS did not differ according to the donor type. The cumulative incidence of relapse for patients transplanted in remission was 26% at 2 years after transplantation. Among patients with MDS or AML in remission at the time of transplantation, the 1-year and 2-year EFS were 61 and 52%, respectively. The cumulative incidence of relapse for patients with AML/MDS that were in complete remission at the time of allografting was 28% at 2 years. AML/MDS patients who were not in complete remission at the time of transplantation had a worse EFS than patients in complete remission but the difference was not statistically significant (P ¼ 0.26), although the presence of circulating blasts in patients with active disease was associated with significantly poorer outcome compared to patients in complete remission (P ¼ 0.01; Fig. 3 ). In conclusion, high-dose posttransplantation cyclophosphamide is effective as sole prophylaxis of GvHD after HLA-matched alloHSCT and does not appear to eliminate the allogeneic GvL effect in patients with advanced hematologic malignancies.
The ability to shorten the duration of postgrafting immunosuppression after HLA-matched alloHSCT with highdose posttransplantation cyclophosphamide was marked by prompt immune reconstitution and a low incidence of opportunistic infections. Among 54 patients studied consecutively, the median absolute lymphocyte counts on day 30 and day 60 after transplantation were 440 and greater than 700/ml, respectively. The median CD4 þ T cell count on day 60 after transplantation was 119/ml. Levels of Foxp3 mRNA, the signature transcript of regulatory T cells, in the peripheral blood of patients who did not develop GvHD were significantly greater than those detected in patients who developed GvHD. These results correlated with significantly lower levels of CD4
þ cells in the blood of patients who developed GvHD. A lack of GvHD also correlated with high levels of IL-1Ra and TGF-b (mRNA transcripts), whereas the development of GvHD correlated with high levels of IFN-g, IP-10, TNF-a and IL-6 [47] . No patients died of CMV or invasive fungal infection. Reactivation of Graft-versus-host disease prevention Luznik et al. 497 CMV occurred in 24% of patients, and there were only two documented case of CMV disease. The rapid recovery of CMV-specific immunity correlated with the results of invitro ELISPOT assays. The frequency of cells secreting interferon gamma in response to stimulation with pentadecapeptides of the immunodominant CMV protein, pp65, at day 30-60 after alloHSCT did not differ from pretransplantation specimens from CMV-seropositive donor-recipient pairs. The absence of posttransplantation EpsteinBarrvirus-associatedlymphoproliferativediseaseisanother indicator of the prompt immunologic recovery seen with posttransplantation cyclophosphamide.
Conclusion
Preclinical results suggesting that high-dose cyclophosphamide given after transplantation can prevent rejection and GvHD had been successfully incorporated in conditioning strategies using HLA-mismatched and HLA-matched donors. High-dose posttransplantation cyclophosphamide facilitates partially HLA-mismatched HSCT without severe GvHD and can mitigate if not completely nullify the negative impact of HLA-disparity on transplantation outcome. High-dose cyclophosphamide is also effective as single agent, short course prophylaxis of GvHD after myeloablative conditioning and HLA-matched alloBMT. The first step in the ongoing development of posttransplantation cyclophosphamide for GvHD prophylaxis is to determine whether these data can be replicated in multicenter trials. Nonetheless, the overall ability of high-dose posttransplant cyclophosphamide to limit the use of posttransplant immunosuppression and thus allow improved immune reconstitution makes an excellent platform for the addition of novel strategies to decrease relapse. Such strategies include vaccinating donors against tumor antigens, use of posttransplant vaccines, and novel posttransplantation adoptive immunotherapy with donor T and/or natural killer cells. By promoting bidirectional transplantation tolerance, high-dose posttransplantation cyclophosphamide creates the possibility of using alloBMT to treat autoimmune diseases and nonmalignant hematologic disorders and to induce tolerance to solid organ transplants through induction of donor hematopoietic chimerism.
